- Home
- GTEC vs ENLV Comparison
GTEC vs ENLV Comparison
Compare GTEC & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | ENLV |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | Israel |
| Employees | 345 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 26.6M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | GTEC | ENLV |
|---|---|---|
| Price | $1.05 | $0.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 192.8K | ★ 11.5M |
| Earning Date | 11-07-2025 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | N/A |
| Revenue This Year | $5.64 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | $1.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.83 |
| 52 Week High | $2.92 | $2.10 |
Technical Indicators
Market Signals| Indicator | GTEC | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 43.10 |
| Support Level | $0.99 | $0.89 |
| Resistance Level | $1.17 | $1.25 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 52.00 | 5.26 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.